Aurobindo Pharma received its final approval from the US Food & Drug Administration (USFDA) to manufacture and market Flucytosine Capsules, 250 mg and 500 mg.
Flucytosine Capsules are used for the treatment of serious infections caused by susceptible strains of Candida and Cryptococcus. The Capsules are a generic version of Bausch Health’s Ancobon Capsules and the capsules will be launched in June 2020.
A total of 429 ANDA approvals has been granted to Aurobindo (401 Final approvals including 23 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.
